ERBB2 and non-small cell lung carcinoma: For this 69-year-old male patient with advanced HER2 exon 20 mutated NSCLC and widespread metastases to the lungs, liver, bones and brain, T-DXd demonstrated promising efficacy and safety for more than 13 months since diagnosis.